You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

receptor-tyrosine-kinase-inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)

Recruiting
  • Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
  • Topical Timolol
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Nov 14, 2023

Liposarcoma, Metastatic Liposarcoma Trial in Boston, Saint Louis, New York (MGCD516)

Active, not recruiting
  • Liposarcoma
  • Metastatic Liposarcoma
  • Boston, Massachusetts
  • +2 more
Nov 23, 2022

Stage II Renal Cell Cancer, Stage III Renal Cell Cancer Trial (tivozanib, therapeutic conventional surgery)

Withdrawn
  • Stage II Renal Cell Cancer
  • Stage III Renal Cell Cancer
  • (no location specified)
Aug 11, 2022

NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
May 23, 2023

NSCLC Trial (AK119, AK112, Pemetrexed)

Not yet recruiting
  • NSCLC
  • (no location specified)
Nov 23, 2022

NSCLC Trial in Seoul (BBT-176, Cetuximab)

Recruiting
  • NSCLC
  • Seongnam-si, Gyeonggi-do, Korea, Republic of
  • +3 more
Jan 6, 2023

Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

Active, not recruiting
  • Neoplasm
  • Beijing, China
  • +5 more
Jan 31, 2023

Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)

Recruiting
  • Non-Squamous Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Sep 22, 2022

NSCLC Stage IV Trial in Taipei (therapeutic thoracic surgery, Afatinib)

Recruiting
  • NSCLC Stage IV
  • Taipei, Taiwan
  • +1 more
Mar 8, 2022

Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer Trial in Buffalo (dovitinib lactate,

Completed
  • Adenocarcinoma of the Pancreas
  • +3 more
  • dovitinib lactate
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 20, 2022

NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • (no location specified)
Mar 27, 2023

NSCLC Trial in Australia, China, Korea, Republic of (AZD9291)

Active, not recruiting
Has Results
  • Non-Small Cell Lung Cancer
  • Kogarah, Australia
  • +29 more
Oct 20, 2022

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Duarte, California
  • +14 more
Jan 27, 2023

Sarcoma, Malignant Peripheral Nerve Sheath Tumors Trial in United States (PLX3397, Sirolimus)

Recruiting
  • Sarcoma
  • Malignant Peripheral Nerve Sheath Tumors
  • Iowa City, Iowa
  • +4 more
Aug 26, 2021

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +3 more
  • New Haven, Connecticut
  • +4 more
Jan 27, 2023

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase

Recruiting
  • Liver Transplant
  • PVHA or TACE
  • Shanghai, Shanghai, China
    The value of tumor feeding vessels deprivation combined with tyr
Nov 26, 2022

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Non Small Cell Lung Cancer Trial in China (XZP-5809-TT1 Tablet)

Recruiting
  • Non Small Cell Lung Cancer
  • XZP-5809-TT1 Tablet
  • Beijing, Beijing, China
  • +4 more
Mar 17, 2021

Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

Recruiting
  • Liver Neoplasms
  • Tislelizumab plus tyrosine kinase inhibitor
  • Beijing, Beijing, China
    302 Hospital
Sep 22, 2023

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib,

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Acalabrutinib
  • CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
  • Duarte, California
    City of Hope Comprehensive Cancer Center
Jun 16, 2022

HER2/Neu+ Uterine Serous Carcinoma Trial in Tucson, New Haven, Boston (Afatinib)

Recruiting
  • HER2/Neu+ Uterine Serous Carcinoma
  • Tucson, Arizona
  • +2 more
Feb 2, 2022

Lung Tumors Trial in Gyeonggi-do, Incheon, Seoul (lazertinib(YH25448))

Recruiting
  • Lung Neoplasms
  • Gyeonggi-do, Korea, Republic of
  • +5 more
Apr 19, 2022

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

Recruiting
  • CML
  • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
  • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
    FUNDALEU
Jun 29, 2023